TLRY Stock Risk & Deep Value Analysis
Tilray Brands Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About TLRY Stock
We analyzed Tilray Brands Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TLRY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
TLRY Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is the continued delay or failure of significant cannabis regulatory reform in the US, which underpins much of Tilray's long-term growth thesis. Without this catalyst, the company may continue to struggle with high debt, negative GAAP earnings, and ongoing dilution, preventing it from reaching sustained profitability and eroding shareholder value over time.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Substantial debt load relative to cash flow and current market cap.
- ⚠
Persistent shareholder dilution as a primary means of capital raising.
- ⚠
Inconsistent GAAP profitability despite positive adjusted EBITDA.
- ⚠
Heavy reliance on a major, uncertain regulatory event (US federal legalization).
Upcoming Risk Events
- 📅
Slower-than-expected progress on US/German cannabis reform
- 📅
Higher-than-anticipated shareholder dilution to fund operations or acquisitions
- 📅
Intensified competition in Canadian and European cannabis markets
When to Reconsider
- 🚪
Exit if quarterly revenue growth stagnates or declines for two consecutive quarters.
- 🚪
Sell if debt-to-equity ratio significantly worsens (e.g., above 3.0) without a clear path to reduction.
- 🚪
Exit if US federal cannabis legalization appears unlikely for another 3+ years.
Unlock TLRY Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Tilray Brands Inc (TLRY) Do?
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,842
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the company provides entertainment products. It offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Tilray Craft, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Tilray Medical, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Cruisies, Atwater Brewery, Hiball Energy, Liquid Love, Hop Valley Brewing, Redhook Brewery, Revolver Brewing, Square Mile Cider, Mock One, Widmer Brothers Brewing, Runner's High Brewing Company, SweetWater Brewing Company, Terrapin Beer Co., Happy Flower, Fizzy Jane's, Herb & Bloom, 420 Fizz, and Fresh Hemp Foods brands. The company sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
Visit Tilray Brands Inc WebsiteInvestment Thesis
Tilray Brands represents a high-risk, high-reward play on the global cannabis market, particularly with its strategic positioning for US federal legalization and its diversified CPG assets providing some revenue stability. Success hinges on management's ability to capitalize on emerging international cannabis markets and execute on a cost-efficient strategy while awaiting significant regulatory catalysts.
Is TLRY Stock Undervalued?
Unlock the full AI analysis for TLRY
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
TLRY Price Targets & Strategy
12-Month Target
$9.50
Bull Case
$15.00
Bear Case
$4.00
Valuation Basis
Based on 2.0x forward P/S applied to $1.2B est. FY27 revenue, assuming modest CPG growth and initial cannabis market share in new regulated markets.
Entry Strategy
Dollar-cost average between $5.50-$6.00 (near recent support levels and current valuation). Avoid large lump-sum buys given regulatory uncertainty.
Exit Strategy
Take 30% profit at $10.00, another 30% at $15.00. Stop-loss at $4.50 if fundamental outlook deteriorates or major negative regulatory news emerges.
Portfolio Allocation
3-5% for moderate risk tolerance, 7-10% for aggressive portfolios due to high speculative nature.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does TLRY Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
3 Identified
The moat is primarily derived from established global supply chains, brand recognition in nascent markets, and a diverse product portfolio, making it somewhat resilient but susceptible to intense competition and regulatory changes. Its CPG brands provide a more stable, albeit smaller, moat.
Moat Erosion Risks
- •Increased competition from new entrants or larger CPG/pharma companies.
- •Regulatory shifts favoring local cultivators or different business models.
- •Inability to establish strong brand loyalty in rapidly evolving markets.
TLRY Competitive Moat Analysis
Sign up to see competitive advantages
TLRY Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish. Retail investors often exhibit speculative enthusiasm for cannabis stocks, particularly around legalization news, but significant skepticism remains regarding financial performance.
Institutional Sentiment
Neutral. Institutional investors are cautious due to regulatory uncertainty and financial performance, but some may hold positions for long-term speculative upside linked to US legalization.
Insider Activity (Form 4)
No specific recent Form 4 filings indicating significant open market buys or sells were provided in the research. However, ongoing shareholder dilution from convertible debt or equity offerings has been a historical trend.
Options Flow
Normal options activity, with a balance of speculative calls and protective puts, reflecting mixed sentiment regarding near-term price movements and the impact of regulatory news.
Earnings Intelligence
Next Earnings
Estimated early-April 2026 (for Q3 FY26)
Surprise Probability
Medium
Historical Earnings Pattern
Tilray's stock often experiences volatility around earnings, reacting strongly to updates on international expansion, US legalization prospects, and improvements (or lack thereof) in adjusted EBITDA and net losses. Strong guidance can lead to rallies, while misses or conservative outlooks can result in sell-offs.
Key Metrics to Watch
Competitive Position
Top Competitor
SNDL (SNDL)
Market Share Trend
Stable to slightly gaining in specific international markets (e.g., Germany medical cannabis). In Canadian recreational, faces intense competition, leading to a stable but challenged position. CPG segment shows stable to growing share.
Valuation vs Peers
Tilray trades at a comparable EV/Sales multiple to other large Canadian LPs, possibly at a slight premium due to its international footprint and CPG diversification. However, traditional P/E is not applicable due to ongoing losses.
Competitive Advantages
- •Global cultivation and distribution infrastructure (EU-GMP certified)
- •Diversified CPG portfolio (craft beverages, hemp foods)
- •First-mover advantage and established brands in several international medical cannabis markets
- •Strategic optionality for US market entry
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive TLRY Stock Higher?
Near-Term (0-6 months)
- •Q3 FY26 Earnings Report (Estimated early-April 2026)
- •Progress on German cannabis legalization (adult-use pilot programs)
- •New product launches in CPG or medical cannabis segments
Medium-Term (6-18 months)
- •Further strategic acquisitions in US cannabis (post-legalization trigger)
- •Expansion of CPG distribution networks
- •European market share gains in medical and recreational cannabis
Long-Term (18+ months)
- •US federal cannabis legalization and subsequent market entry
- •Achievement of consistent GAAP profitability and positive free cash flow
- •Consolidation of market leadership in key international cannabis markets
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for TLRY?
- ✓
Clear progress on US federal cannabis reform (e.g., SAFE Banking or rescheduling)
- ✓
Consistent reduction in GAAP losses and achievement of positive free cash flow
- ✓
Significant market share gains in key European cannabis markets.
Bull Case Analysis
See what could go right with Premium
Competing with TLRY
See how Tilray Brands Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Tilray Brands Inc TLRY | — | 6.2 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Tilray Brands Inc (TLRY)?
As of March 30, 2026, Tilray Brands Inc has a DVR Score of 6.2 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does Tilray Brands Inc use?
TLRY is the ticker symbol for Tilray Brands Inc. The company trades on the NMS.
What is the risk level for TLRY stock?
Our analysis rates Tilray Brands Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the TLRY DVR analysis updated?
Our AI-powered analysis of Tilray Brands Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 30, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TLRY (Tilray Brands Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.